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Table I. Right ventricular hemodynamic results after creation of an arteriovenous anastomosis and administration 
of intravenous doxorubicin 
RVP(mmHg) PAP (mm Hg) PCWP(mmHg) RAP (mmHg) 
Baseline 
One month after anastomosis 
One month after doxorubicin or 2 months after anastomosis 
25 ± 3 
32 ± 2* 
46 ± 2*t 
22 ±2 
28 ± 2* 
46 ± 5*t 
9±2 
14± I 
19 ± 3 
6±1 
17 ± 3* 
26 ± 4*t 
PAp, Pulmonary arterial pressure; pewp, pulmonary capillary wedge pressure; RAP, right atrial pressure; RVp, right ventricular pressure. 
*p < .05 versus baseline. 
t P < .05 versus results at I month. 
Table II. Left ventricular hemodynamic results after creation of an arteriovenous anastomosis and administration 
of intravenous doxorubicin 
ABP-S ABP-D LVP-S LVP-D HR CI LVEF 
(mmHg) (mmHg) (mmHg) (mmHg) (beats/min) (Uminlm2) (%) 
Baseline 105±9 63 ± 8 105±9 9±4 112±3 3.8 ± 0.3 77±5 
One month after anastomosis 104± 10 56±5 104± !O II ±3 123 ± 5* 3.8 ±0.2 66±4 
One month after doxorubicin 86 ± 5*t 54±4 86± 5*t 20± 2*t 142 ±3*t 2.6 ± O.3*t 43 ± 6*t 
or 2 months after anastomosis 
ABP-S, Aortic blood pressure-systole; ABP-D, aortic blood pressure----<liastole; C/, cardiac index; HR, heart rate; LVEF, left ventricular ejection fraction; qP-s, 
left ventricular pressure-systole; LVP-D, left ventricular pressure----<liastole. 
* P < .05 versus baseline. 
tP < .05 versus results at I month. 
The combined evidence of these investigations points 
toward the necessity of using both an arteriovenous anasto-
mosis and doxorubicin for a stable model of bilateral chronic 
heart failure. A model of bilateral heart failure can be espe-
cially useful for comparing surgical methods of treating 
pre-end-stage congestive heart failure, that is, cardiomyoplas-
ty, partial ventriculectomy, or implantation of artificial ven-
tricular assist devices. 
REFERENCES 
Valeri S. Chekanov, MD, PhD 
Milwaukee Heart Institute 
Sinai Samaritan Medical Center 
PO Box 342 
960 North Twelfth St 
Milwaukee, WI 53201-0342 
I. Toyoda Y, Okada M, Kashem MA. A canine model of dilated car-
diomyopathy induced by repetitive intracoronary doxorubicin 
administration. J Thorac Cardiovasc Surg 1998; 115: 1367-73. 
2. Smink M, Van der Veen FH, Prenger K, Schrender YY, Ventricular 
reduction surgery in grafts with dilated hearts. Basic Appl 
Myology 1/:198;8:236. 
12/8/94496 
High hem~tocrit value is a risk factor for myocardial 
infarction 
To the Editor: 
I read with interest the article on the positive correlation 
between the hematocrit value and the frequency of myocardial 
infarction (MI) after coronary artery bypass grafting (CABG) 
by Spiess and associates. l That a high hematocrit value was 
associated with an increased risk for MI has been known since 
the early 1960s.2-6 George Burch, who wrote numerous arti-
cles on this subject,z-6 advocated bloodletting in patients with 
coronary artery disease with a high hematocrit value'? He 
showed that the clinical state of these patients definitely 
improved when their hematocrit was reduced to "average nor-
mal" levels.6-s 
Burch8 wondered why bloodletting was rarely used as a 
therapeutic measure for these patients. It might be appropriate 
to quote what Burch said in 1979: 
It is well known that a high hematocrit is associated 
with high viscosity and that a highly viscous fluid re-
quires more work of the pump to circulate it than does a 
less viscous liquid. Furthermore, the flow of highly vis-
cous fluid is reduced, even with all else being equal. 
Nevertheless, physicians fail to bleed patients with active 
coronary disease and myocardial ischemia, whose hema-
tocrit is high and whose blood viscosity is increased. It 
has been shown that bloodletting in patients with 
ischemic heart disease definitely improved the clinical 
state of these patients when their hematocrit was reduced 
to average normal levels .... 
Could it be that the procedure is rarely used because it 
appears to be "old-fashioned," "antique," and not "mod-
ern"? If the concept is good and the clinical results often 
dramatic, why not use it? Just because "bloodletting" is 
a procedure of the old days and one that was misused, 
this does not justify not using it today. 
Some old things are good. Antiques are desirable and 
appreciated and antiquities are even more precious and 
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valuable. People by the millions visit the King Tut exhib-
it-including doctors. But, the King Tut exhibit is not 
modern. That which is good or useful must be pre-
served-even bloodletting for definite clinical indica-
tions, such as with angina pectoris and other types of 
ischemic heart disease. * 
I propose that CABG is simply a more elegant and more 
sophisticated method of bloodletting. The finding by Spiess 
and associates! in their study of 2202 patients that a low 
hematocrit value (less than 24%) at the conclusion of CABG 
protects against Q-wave MI is a modern proof of what Burch 
predicted 36 years ago. 
Tsung O. Cheng, MD 
Professor of Medicine 
The George Washington University Medical Center 
Washington, DC 20037 
*Reprinted from Burch GE. Of bloodletting. Am Heart J 1979; 
98:666, published by The C. V. Mosby Company, St Louis, Mo. 
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